This document is the transcript of the Q1 FY27 Earnings Conference Call for Acutaas Chemicals Limited, held on July 24, 2026, and submitted to the exchanges as a regulatory disclosure pursuant to Regulation 30 of SEBI LODR.

  • Event Type: The event was a post-results earnings conference call to discuss the financial results for the quarter ended June 30, 2026 (Q1 FY27), hosted by Nuvama Institutional Equities.
  • Date and Time: The call was held on July 24, 2026. A specific time was not mentioned in the transcript.
  • Purpose: The stated purpose was to discuss the company's Q1 FY27 financial results and provide a business update.
  • Earnings Timing: The call was held post-announcement of the quarterly financial results.
  • Management Participants: The management participants were Mr. Naresh Patel (Chairman and Managing Director), Mr. Abhishek Patel (President – Strategy), and Mr. Bhavin Shah (Chief Financial Officer). The call was moderated by Mr. Archit Joshi from Nuvama Institutional Equities.
  • Availability of Materials: The company confirmed that the audio and transcript of the conference call would be made available on the company's website (www.acutaas.com) and the stock exchanges. The audio is the copyright material of Acutaas Chemicals.
  • UPSI Statement: The company included standard forward-looking statement and risk disclaimers but did not include a specific statement confirming that no Unpublished Price Sensitive Information (UPSI) would be shared.

Financial Highlights & Strategic Themes (As Disclosed)

The call included a discussion of the company's financial performance and strategic direction for Q1 FY27.

  • Financial Period Discussed: Q1 FY27 (Quarter ended June 30, 2026).
  • Financial Performance: Revenue from operations was INR 329.7 crores, a growth of 59.1% YoY. Gross Profit was INR 190.9 crores (57.9% margin, +466 bps YoY). EBITDA was INR 113.1 crores (34.3% margin, +973 bps YoY). PAT was INR 74.9 crores (22.7% margin, +151 bps YoY).
  • Segment Performance: The Advanced Pharmaceutical Intermediates segment revenue was INR 292.7 crores (76.5% YoY growth). The Specialty Chemicals segment revenue was INR 37 crores (-10.6% YoY), reflecting the planned phase-out of commodity chemicals.
  • Forward-Looking Statements: Management provided full-year revenue growth guidance of 25% for FY27 with stable margins similar to FY26. They expressed high confidence in the rapid ramp-up of the new battery chemicals business and the long-term structural demand for semiconductor chemicals.
  • Strategic Updates: Key updates included the successful completion of trial runs and start of commercial supply from the new battery chemicals plant. Construction of the Indichem semiconductor plant in Korea is ahead of schedule, with capex expected to be completed by the end of Q2 FY27. The company is also planning for a new R&D center and land acquisition for future capacity expansion.

Additional Notes Section

  • Attachments: The regulatory filing intimates that the transcript was enclosed as an attachment to the letter sent to the exchanges.
  • Financial Data: Significant financial data was disclosed and discussed during the earnings call, as detailed in the summary above.
  • Logistical Details: The transcript contained detailed Q&A with analysts but did not include operational dial-in numbers or access codes.